Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification
MetadataShow full item record
INTRODUCTION: Chronic kidney disease-mineral and bone disorders (CKD-MBD) are associated with costly complications and dismal hard-outcomes. AREAS COVERED: In two comprehensive articles we review contemporary and future pharmacological options for treatment of phosphate (P) imbalance (part 1) and hyperparathyroidism (this part 2), taking into account CKD-accelerated cardiovascular calcification (CVC) processes. EXPERT OPINION: Improvements in CKD-MBD require an integral approach, addressing all three components of the CKD-MBD triad. Here, initial guidance to control hyperparathyroidism is provided, taking into account the presence/absence of CVC. We include also measures for patients at risk of adynamic bone disease or suffering from calciphylaxis. Many epidemiological studies (relating to vitamin D) and thorough analyses of recent randomized clinical trials (of cinacalcet) point towards benefits of attempting to improve biochemical parameters while trying to, at least, avoid progression of CVC by more rational use of intestinal P-binders and low-dose vitamin D derivatives and/or calcimimetics. This approach does not seem to be far away from significantly improving hard-outcomes, at least in the dialysis population. The availability of new drugs and the performance of randomized clinical trials should ultimately lead to define earlier, clearer, and more cost-effective patient stratification and biochemical targets with consequent significant clinical improvements.
Is part ofExpert Opinion On Pharmacotherapy, 2016, vol. 17, num. 10, p. 1363-1373
European research projects
Showing items related by title, author, creator and subject.
Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification Bover, J.; Ureña-Torres, P.; Lloret, MJ.; Ruiz-García, C.; DaSilva, I.; Diaz-Encarnacion, MM.; Mercado, C.; Mateu, S.; Fernández i Giráldez, Elvira; Ballarin, J. (Taylor & Francis, 2016-06-17)NTRODUCTION: Chronic kidney disease-mineral and bone disorders (CKD-MBD), involving a triad of laboratory and bone abnormalities, and tissue calcifications, are associated with dismal hard-outcomes. AREAS COVERED: In two ...
Carmona, Andrés; Agüera, Maria L.; Luna-Ruiz, Carlos; Buendía, Paula; Calleros-Basilio, Laura; García-Jerez, Andrea; Rodríguez-Puyol, Manuel; Arias, Manuel; Arias-Guillen, Marta; Arriba, Gabriel de; Ballarin, José; Bernis, Carmen; Fernández i Giráldez, Elvira; García-Rebollo, Sagrario; Mancha, Javier; Peso, Gloria del; Pérez, Estefanía; Poch, Esteban; Portolés, José M.; Rodríguez-Puyol, Diego; Sánchez-Villanueva, Rafael; Sarró, Felipe; Torres, Armando; Martín-Malo, Alejandro; Aljama, Pedro; Ramírez, Rafael; Carracedo, Júlia (American Physiological Society, 2017-04-01)Patients with Stage 5 chronic kidney disease who are on hemodialysis (HD) remain in a chronic inflammatory state, characterized by the accumulation of uremic toxins that induce endothelial damage and cardiovascular disease ...
Mineral metabolism factors predict accelerated progression of common carotid intima-media thickness in chronic kidney disease: the NEFRONA study Abajo, María; Betriu i Bars, M. Àngels; Arroyo, David; Gracia, Marta; Pino, María Dolores del; Martínez, Isabel; Valdivielso Revilla, José Manuel; Fernández i Giráldez, Elvira (Oxford University Press, 2017-08-27)BACK GROUND: The leading cause of premature death in chronic kidney disease (CKD) is cardiovascular disease (CVD), but risk assessment in renal patients is challenging. The aim of the study was to analyse the factors that ...